ADC raises $200M private placement

On Oct. 23, antibody-drug conjugate company ADC Therapeutics S.A. (Épalinges, Switzerland) raised $200 million in a private placement from Auven Therapeutics Management, Redmile, the Wild Family Office and AstraZeneca plc (LSE:AZN; NYSE:AZN).

Next year, ADC Therapeutics plans to start registrational trials of lead candidates ADCT-301 (HuMax-TAC-ADC) and ADCT-402 to treat lymphoma and leukemia subtypes...